Tyra Biosciences to Join Upcoming Investor Events for Insight into Precision Medicines

Tyra Biosciences Set for Upcoming Investor Engagements

Tyra Biosciences, Inc. (Nasdaq: TYRA), a dynamic player in the biotechnology sector, has announced its participation in prominent investor events, promising a deeper insight into the development of next-generation precision medicines aimed at targeting significant opportunities within Fibroblast Growth Factor Receptor (FGFR) biology. The company, headquartered in Carlsbad, California, is at the forefront of clinical-stage biotechnology, driving innovation for both targeted oncology and genetically defined disorders.

The first event in their schedule is the Virtual H.C. Wainwright "HCW@Home" series. Management will engage in a fireside chat format to discuss the strategic direction and groundbreaking work Tyra is undertaking in the field. This presentation is set to take place on August 21, 2025, at 11 AM ET. Investors and interested parties can tune in for the live broadcast, which will also have an option for replay later on.

Following this, Tyra will participate in the 27th Annual Global Investment Conference by H.C. Wainwright on September 10, 2025, where they will again hold a fireside chat alongside one-on-one investor meetings in New York, NY. This event promises a unique opportunity for investors to gain insights directly from the company’s leadership about the current and future state of Tyra’s clinical programs and research initiatives.

Company Overview

Tyra Biosciences stands out in the competitive biotech landscape due to its innovative approach in precision medicine. Their specialized platform, known as SNÅP, facilitates rapid and precise drug design, allowing for targeted therapies that anticipate genetic changes likely to spur resistance to existing treatments.

The company’s lead precision medicine candidate, dabogratinib, is positioned as a potential first-in-class selective FGFR3 inhibitor. This innovative drug aims to bypass the adverse effects commonly associated with the inhibition of FGFR1, FGFR2, and FGFR4, thus offering new hope for patients potentially affected by FGFR3 gatekeeper mutations. Its clinical studies are primarily focused on intermediate risk non-muscle invasive bladder cancer through the SURF302 trial, as well as pediatric cases of achondroplasia via BEACH301. Additionally, there are plans for future studies addressing metastatic urothelial cancer.

Expanding on their pipeline, Tyra is also working on TYRA-430, a groundbreaking oral investigational FGFR4/3-biased inhibitor targeting FGF19+/FGFR4-dominant cancers, participating in the SURF431 study for advanced hepatocellular carcinoma. Another promising candidate, TYRA-200, is being evaluated in the SURF201 study as an oral investigational FGFR1/2/3 inhibitor for metastatic intrahepatic cholangiocarcinoma.

In summary, Tyra Biosciences is carving out a distinct place in biotechnology by focusing on precision medicine aimed at improving treatment outcomes for patients with specific genetic profiles. As they prepare for these upcoming investor events, both the biotech community and investors alike are keenly poised to discover how Tyra's groundbreaking approaches evolve and impact the healthcare landscape.

For those interested in learning more about Tyra Biosciences, their innovative scientific endeavors, and details regarding their drug pipeline, further information can be found on their official website www.tyra.bio and on LinkedIn, where ongoing engagement with their community is encouraged.